Skip to main content

Aldeyra Therapeutics, Inc.

ALDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001341235

In the last 90 days, Aldeyra Therapeutics, Inc. insiders filed 3 open-market purchases and 0 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $77.7M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 17, 2026
$41.9M
Insider buysLast 90 days, $140.3K in total
3
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −19 vs. previous quarter
107
13F valueReported value at the end of Q2 2026
$77.7M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$33.8M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
3.16M
Shares sold short
Change
−26.8K
−0.8% vs. previous
Days to cover
3.44
At average daily volume

Superinvestors holding ALDX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ALDX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Aldeyra Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)5:33 PM ETNov 124 daysDeptula-Hicks Darlene MDirectorPPurchase+7.50K$0.65+$4.88KNew position7.50K after
Nov 13, 2026 (view filing)4:31 PM ETNov 112 daysAlfieri MichaelPrincipal Financial OfficerPPurchase+10.0K$0.65+$6.50K+133.3%17.5K after
Nov 13, 2026 (view filing)4:26 PM ETNov 112 daysDouglas RichardDirectorPPurchase+200.0K$0.6445+$128.9K+102.6%395.0K after
Jun 5, 2026 (view filing)Jun 32 daysBrady Todd CPresident and CEOPPurchase+250.0K$1.67+$417.5K+17.0%1.72M after
Mar 20, 2026 (view filing)Mar 191 dayDouglas RichardDirectorPPurchase+70.0K$1.40+$98.0K+56.0%195.0K after
Mar 19, 2026 (view filing)Mar 181 dayAlfieri MichaelPrincipal Financial OfficerPPurchase+5.00K$1.42+$7.10K+200.0%7.50K after
Aug 15, 2025 (view filing)Aug 132 daysAlfieri MichaelPrincipal Financial OfficerPPurchase+2.50K$5.30+$13.3KNew position2.50K after
Aug 13, 2025 (view filing)Aug 112 daysMachatha StephenChief Development OfficerSSale−22.1K$5.15−$113.7K−9.1%221.8K after
Apr 7, 2025 (view filing)6:43 PM ETApr 34 daysEdelman Joseph and 2 others10% OwnerSSale−3.40M$1.42−$4.83M−36.7%5.88M after
Oct 21, 2024 (view filing)May 3, 2021-Apr 12, 20231,267 daysLateMiller-Rich NancyDirectorPPurchase+922$11.33+$10.4KNew position922 after2 lots

Top 10 13F holders, Q2 2026

See all 107 holders

The largest institutional positions in Aldeyra Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding ALDX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Knoll Capital Management, LLC5,475,516$11.7M5.59%00.0%Unchanged
AQR Capital Management LLC3,751,558$7.99M0.00%+921,683+32.6%Added
Kingdon Capital Management, L.L.C.2,652,315$5.65M0.76%+500,000+23.2%Added
Vanguard Capital Management LLC2,361,796$5.03M0.00%−1,946−0.1%Reduced
D. E. Shaw & Co., Inc.1,940,338$4.13M0.00%+536,348+38.2%Added
Marshall Wace, LLP1,506,974$3.21M0.00%+1,377,281+1,062.0%Added
683 Capital Management, LLC1,450,000$3.09M0.28%−50,000−3.3%Reduced
Jane Street Group, LLC1,375,115$2.93M0.00%+406,224+41.9%Added
BlackRock, Inc.1,257,243$2.68M0.00%−2,506,644−66.6%Reduced
Qube Research & Technologies Ltd1,128,803$2.40M0.00%+1,041,725+1,196.3%Added

Holders of 5% or more of ALDX

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aldeyra Therapeutics, Inc..

Largest holders of ALDX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Barclays PLC13G5.48%3.31M sharesNewNov 6, 20261 filingNov 6, 2026SEC